Welcome to our dedicated page for Vaxart SEC filings (Ticker: VXRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaxart, Inc. filings document a clinical-stage biotechnology issuer focused on oral recombinant pill vaccines and a common stock quoted on the OTCQX Best Market under the symbol VXRT. The company’s regulatory record includes financial-result 8-K reports, registration statements and registration-rights disclosures tied to common stock financing, and exhibits covering material agreements.
The filings also cover board appointments and independence determinations, lease terminations and facility changes, capital structure items, revenue categories such as government contract and collaboration revenue, and formal market-status records, including a Form 25 for removal of the common stock from Nasdaq listing and registration.
Vaxart director Kevin Finney reported equity awards dated July 16, 2026. He received 39,400 shares of Common Stock upon vesting of restricted stock units, bringing his direct holdings to 244,171 shares. He was also granted 78,700 stock options with a $0.5149 exercise price, expiring July 16, 2036. Both the RSU shares and options vest on the earlier of the date immediately prior to Vaxart’s 2027 annual meeting of stockholders and July 16, 2027, the first anniversary of the grant.
Vaxart, Inc. director James B. Breitmeyer reported equity awards dated July 16, 2026. He acquired 8,315 shares of common stock in connection with restricted stock units that will vest on the earlier of the date immediately prior to the 2027 annual stockholder meeting and July 16, 2027, bringing his direct holdings to 87,115 shares. He was also granted options on 16,610 shares at an exercise price of $0.5149 per share, expiring July 16, 2036, with the options subject to the same vesting schedule.
Vaxart, Inc. director Elaine J Heron reported equity compensation awards dated July 16, 2026. She acquired 39,400 shares of Common Stock in connection with restricted stock units, bringing her direct common share holdings to 135,966. She was also granted 78,700 Stock Options to buy Common Stock at an exercise price of $0.5149 per share, expiring on July 16, 2036. Footnotes state that both the restricted stock unit award and the option award vest on the earlier of the date immediately prior to Vaxart’s 2027 annual meeting of stockholders and July 16, 2027.
Vaxart, Inc. director Watson W. Mark reported compensation-related equity awards. He acquired 39,400 shares of common stock at no cost in connection with restricted stock units, and a grant of 78,700 stock options with a $0.5149 exercise price, expiring July 16, 2036. Both the shares and options are scheduled to vest on the earlier of the date immediately prior to Vaxart’s 2027 annual stockholders’ meeting and July 16, 2027. Following these awards, he directly holds 173,525 common shares and 78,700 options.
Vaxart, Inc. director David E. Wheadon received equity awards on July 16, 2026. He was granted 39,400 shares of common stock, bringing his direct holdings to 86,150 shares, plus stock options for 78,700 shares at an exercise price of $0.5149, expiring July 16, 2036. Both the stock award and options vest on the earlier of the date immediately prior to Vaxart’s 2027 annual meeting of stockholders and July 16, 2027, the first anniversary of the grant.
Vaxart, Inc. reported the results of its 2026 annual meeting of stockholders held on July 16, 2026. Proxies representing approximately 45.7% of outstanding common shares constituted a quorum. Stockholders elected six directors to serve until the 2027 annual meeting and ratified the selection of WithumSmith+Brown, PC as independent registered public accounting firm for the year ending December 31, 2026. However, stockholders did not approve, on a non-binding, advisory basis, the compensation of the named executive officers, with 46,024,068 votes for, 51,842,781 against and 2,300,962 abstentions, plus 10,463,289 broker non-votes.
The company also described its focus as a clinical-stage biotechnology company developing oral recombinant pill vaccines, including a Phase 2b trial of its oral COVID-19 vaccine candidate supported in part by Project NextGen and the RRPV Consortium.
Vaxart, Inc. reported 12‑month topline safety data from the approximately 400‑participant sentinel safety cohort in its Phase 2b trial of an oral pill COVID‑19 vaccine versus an approved mRNA comparator. Participants received either Vaxart’s oral pill vaccine (201 people) or an mRNA vaccine (199 people) targeting the XBB strain of SARS‑CoV‑2.
No vaccine‑related serious adverse events or sustained Grade 3 or higher adverse events were observed in either arm over 12 months, supporting a favorable safety profile for both regimens in this cohort. The full study includes this sentinel cohort plus about 5,000 participants in a main cohort dosed with vaccines targeting the KP.2 strain, with complete data anticipated in 2027.
The program is supported by Project NextGen through BARDA, ASPR, HHS and NIAID under a Rapid Response Partnership Vehicle Consortium award valued at up to $344.8 million, helping fund development of Vaxart’s proprietary oral pill vaccine platform.
Vaxart, Inc. and a group of stockholders led by Daniel P. Houle entered a Cooperation Agreement that resolves an active proxy contest and withdraws the stockholders' slate of nominees for the 2026 annual meeting.
Under the agreement the Concerned Vaxart Stockholders withdrew their slate and will not vote proxies; the parties agreed to identify and appoint a New Director to the Board within 60 to 90 days from the conclusion of the 2026 Annual Meeting, with that director joining the Nominating and Governance Committee until the 2027 Annual Meeting. The Board also agreed to form two new committees and adopt director ownership and resignation policies in Q3 of fiscal 2026, and company management will meet quarterly with the Concerned Vaxart Stockholders following quarterly earnings.
Vaxart, Inc. entered into a Cooperation Agreement with a stockholder group that resolves a proxy contest ahead of the 2026 Annual Meeting of Stockholders. The stockholder group has withdrawn its competing director nominations and its demand to inspect certain company books and records.
Vaxart and the group will work together in the 60- to 90-day period after the 2026 meeting to select a mutually agreed independent “New Director,” who will join the Board and the Nominating and Corporate Governance Committee and chair a new Stockholder Engagement Committee. The Board will also form a Clinical and Regulatory Affairs Committee, adopt director resignation and stock ownership policies, and refresh key committee leadership.
Management will meet with the stockholder group at least once per fiscal quarter to discuss financial and strategic matters based on public information. Vaxart will reimburse the group’s documented expenses up to $650,000. The agreement includes customary voting, standstill and non-disparagement provisions and runs through a termination date tied to nomination deadlines for the 2027 or potentially 2028 annual meetings.
Vaxart, Inc. entered into a new modification of its BARDA-funded Project NextGen contract, resetting total funding for its Phase 2b oral COVID‑19 pill vaccine trial to approximately $345 million, which is about $116 million lower than the prior modification after trial enrollment was cut roughly in half by a BARDA partial termination.
The revised amount includes about $68 million of firm fixed price funding, with the remainder reimbursing trial preparation and execution costs, and also releases roughly $29 million to complete the study and perform exploratory safety and efficacy analyses. Vaxart expects to report 12‑month data from a 400‑participant sentinel cohort in the coming weeks and from the 5,085‑participant main cohort in the first half of 2027.